Evaluation of in vitro antileishmanial activity of

curcumin and its derivatives “Gallium curcumin,

Indium curcumin and Diacethyle curcumin” by TAHMASEBI, R. et al.
European Review for Medical and Pharmacological Sciences
3306
Abstract. – BACKGROUND AND OBJECTIVES:
Leishmania parasites are intracellular haemoflagel-
lates that infect macrophages of the skin and vis-
cera to produce diseases in their vertebrates
hosts. Antileishmania therapy is based on pen-
tavalent antimony compounds which toxicity of
these agents and the persistence of side effects
are severe. Curcumin was identified to be re-
sponsible for most of the biological effects of
turmeric. Turmeric plant extracts (curcumin and
other derivatives) have anti-inflammatory, anti-
arthritic, antioxidant, anti-microbial, antileishma-
nial, hepato protective, anti-cancer, anti-ulcer
and anti diabetic activity.
MATERIALS AND METHODS: Stock solutions
of curcumin, indium curcumin, diacetylcurcumin
and Gallium curcumin were made up in DMSO.
From the each stock solution serial dilutions
were made with phosphate buffered saline and
100 µl of each prepared concentration was
added to each well of 96-well micro plate. All
tests were performed in triplicate. Negative con-
trol only received RPMI-1640 medium with a par-
asite density of 106 parasites /ml and the posi-
tive control contained varying concentrations of
standard antileishmania compound, Ampho-
tericine B. MTT solution was prepared as 5
mg/ml in RPMI-1640 and 20 µl of this concentra-
tion was added to each well. Antileishmania ef-
fects of test agents and control were evaluated
by using the MTT assay.
RESULTS: Mean growth inhibition of triplicate for
each concentration of test agents and control were
measured. The IC50 values for curcumin, gallium
curcumin [ga (CUR) 3], indium curcumin [in
(CUR)3], Diacethyle Curcumin (DAC ) and Ampho-
tericine B were 38 µg/ml, 32 µg/ml, 26 µg/ml, 52
µg/ml and 20 µg/ml respectively. Indium curcumin
[in (CUR) 3] with IC50 values of 26 µg/ml was more
effective than other three test agents against
Leishmania. Mean growth inhibition of triplicate for
Amphotericine B as control drug, was 20 µg/ml.
CONCLUSIONS: Indium curcumin and Gallium
curcumin complex showed more antileishmanial
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activity than curcumin and diacetylcurcumin and
could be suitable candidates for further investi-
gations.
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Introduction
Leishmania species are intracellular parasitic
haemoflagellates that infect macrophages of the
skin and viscera to produce diseases in their ver-
tebrates hosts. Three major clinical manifesta-
tions of Leishmaniasis are recognised: visceral,
cutaneous and muco-cutaneous Leishmaniasis1.
Antileishmania therapy is based on pentavalent
antimony compounds. The toxicity of these
agents and the persistence of side effects are se-
vere, even after modification of the dose level
and the duration of treatment2. Curcumin is the
active ingredient in the herbal remedy and di-
etary spice turmeric (Curcuma longa Linn). Cur-
cumin was identified to be responsible for most
of the biological effects of turmeric3. In vitro cur-
cumin has anti-Leishmania activity4. Curcumin
has got poor bioavailability but is remarkably
well tolerated and does not appear to be toxic to
animals or humans even at high doses5,6. Anti-
Plasmodium falciparum and anti- Leishmania
major effects of curcumin have also been report-
ed7. Growth of several bacteria like Streptococ-
cus, Staphylococcus and Lactobacillus could be
suppressed by curcumin8,9. The aqueous extract
of turmeric rhizomes has reported the antibacteri-
al effects10. In vitro growth of Helicobacter py-
lori can also be prevented by the use of curcum-
in. Turmeric plant extract (curcumin and other
derivatives) have anti-inflammatory, anti-arthrit-
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ic, antioxidant, anti-microbial, anti-leishmanial,
hepato protective, anti-cancer, anti-ulcer and anti
diabetic activity11. The objective of the present
study was to evaluate the anti-Leishmanial activi-
ty of curcumin, indium curcumin, diacetyl cur-
cumin, and Gallium curcumin compared with
Amphotericine B.
Materials and Methods
Parasite Culture and Test Agents
Leishmania major (MRHO/IR/75/ER) pro-
mastigotes were cultivated in RPMI-1640 (Sig-
ma, St. Louis, MO, USA) medium supplement-
ed with 10% fetal calf serum (FCS) (Sigma, St.
Louis, MO, USA) and 50 mg/ml Ampicillin
(Sigma, Steinheim, Germany). They were
grown in bulk at 25°C, culture tubes were cen-
trifuged at 2500 g for 10 min and early log
phase promastigotes were collected. The para-
sites were washed twice with RPMI-1640 (with-
out FCS) and resuspended in the complete
medium to achieve a final concentration of 106
parasites/ml. The test was performed in 96-well
microtitre plates and each well was filled with
100 µl of culture medium and the plates were
incubated at 27°C for 1 h before the test agents
addition. The test agents in this study were cur-
cumin, indium curcumin [In(CUR)3], diacetyl-
curcumin (DAC) and Gallium curcumin [(GA
(cur)3]. Curcumin (Sigma) was purchased and
then, DAC, In (CUR)3, and Gallium curcumin
were prepared as previously described. Stock
solution of the test agents were made up in DM-
SO (dimethylsulfoxide; Merck, Darmstadt, Ger-
many) to ensure complete solubilization12-15.
From the each stok solution of the test agents
serial dilutions were made with phosphate
buffered saline (PBS) and 100 µl of each pre-
pared concentration was added to each well of
96-well Nunc microtiter plate. All tests were
performed in triplicate. Negative control only
received RPMI-1640 medium with a parasite
density of 106 parasites/ml and the positive con-
trol contained varying concentrations of stan-
dard antileishmania compound, Amphotericine
B (Sigma, Steinheim, Germany). MTT (Sigma,
St. Louis, MO, USA) solution was prepared as
5 mg/ml in RPMI-1640 without phenol red and
filtered through a 0.2 µm filter and 20 µl of this
concentration was added to each well and incu-
bated at 25°C for 72 hours. After this incubation
period and in order to solving the formazan
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crystals, 150 µl of acidic isopropanol was added
to each well. The plate was read on an ELISA
reader (Biotech, Highland Park, Winooski, VT,
USA) using 540 nm as test wavelength and 630
nm as the reference wavelength15.
Statistical Analysis
Data were recorded and analyzed using SPSS
16.0 software (SPSS Inc., Chicago, IL) and p val-
ue < 0.05 was considered significant. To compare
the effects of different concentrations of the test
agents and Amphotericine B as control drug, sta-
tistical analysis was performed using the non
parametric Kruskal-Wallis test and Mann-Whit-
ney U test was used to compare the different cur-
cumin concentrations.
Results
Different concentrations of curcumin, indium
curcumin [In(CUR)3], diacetylcurcumin (DAC)
and Gallium curcumin [(Ga(cur)3] were evaluat-
ed for their in vitro effects against the Leishma-
nia major promastigotes. Mean growth inhibition
of triplicate for each concentration of test agents
and control were measured. The characterization
of leishmanicidal activity of curcumin and its de-
rivatives as test agents and Amphotericine B as
standard drug is summarized in Table I. The IC50
values for curcumin, gallium curcumin
[Ga(CUR)3], indium curcumin [In(CUR)3], Di-
acethyle Curcumin (DAC ) and Amphotericine B
were 38, 32, 26, 52 and 20 µg/ml respectively.
Discussion
Antileishmania therapy is based on pentava-
lent antimony compounds. The toxicity of these
agents and the persistence of side effects are se-
vere, even after modification of the dose level
Cytotoxicity µg/ml
Agents (IC50)
Curcumin 38
Gallium Curcumin [Ga( CUR)3] 32
Indium Curcumin [In(CUR)3] 26
Diacethyle Curcumin (DAC) 52
Amphotericine B 20
Table I.Anti-leishmanial activity of curcumin and its deriv-
atives.
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and the duration of treatment16,17. These problem
regarding the Leismaniases treatment necessitate
the continued effort to identify new improved an-
tileishmanial drugs. As shown in Table I, indium
curcumin [in (CUR) 3] with IC50 values of 26
µg/ml was more effective than other three test
agents against Leishmania promastigotes. The
second effective agent against Leishmania was
Gallium curcumin [Ga(CUR)3] with IC50 of 32
µg/ml. Curcumin with IC50 value of 38 µg/ml is
the third agent and Diacethyle Curcumin (DAC)
with 52 µg/ml is the fourth agent against Leish-
mania promastigotes. mean growth inhibition of
triplicate for Amphotericine B as control drug,
was 20 µg/ml.
Conclusions
indium curcumin and Gallium curcumin com-
plex have more anti-Leishmanial activity than
curcumin and diacetylcurcumin and could be
suitable candidates for further in vivo investiga-
tions. This results is in accordance with Moham-
madi et al study12 which shows that the Gallium
and indium complexes of curcumin had much
lower IC50 values of cytotoxicity in mouse lym-
phoma cells.
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